🏛️ Verified NIH Record • Updated 2024-11-13
Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage (NCT06691945)
🟡 Not Yet Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: The University of Texas Health Science Center, Houston
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to decrease the likelihood of composite postpartum hemorrhage (PPH) morbidity, which consists of i) Estimated or quantified blood loss of 1,500 mL or more, ii) transfusion of any blood products or iii) hysterectomy
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (8 items).
Location: The University of Texas Health Science Center at Houston — Houston, Texas
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Scheduled cesarean delivery
- Multiple gestations
- Delivery at \< 34.0 weeks
- Contraindication to place intrauterine pressure catheter (e.g. HIV)
- Incarcerated subjects
- Major fetal anomalies requiring neonatal surgical intervention
- Stillbirth on admission
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- The University of Texas Health Science Center at Houston — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.